Abstrac
t—The superoxide-generating reaction of adrenaline autoxidation in an alkaline medium, used in vitro to identify the antioxidant properties of various compounds, simulates the complex multistep process of quinoid oxidation of catecholamines (CA) in the body. Sulfur-containing cysteine (Cys) and reduced glutathione (GSH), as well as oxidized glutathione (GSSG), have been shown to inhibit this process. The studied substances considered as inhibitors of quinoid oxidation have been also evaluated as antioxidants. The IC50 values for Cys and GSH were close to 7.5 μM. Inhibition by GSSG was weaker and represented approximately 50–70% of Cys and GSH inhibitory activity. The other sulfur-containing compounds that differ in chemical structure, the amino acids taurine and methionine were ineffective. The interest in this model and the search for effective compounds acting on this reaction is associated with one of the mechanisms of the etiopathogenesis of Parkinson’s disease (PD) discussed in the literature; it is related to impairments of biochemical transformations of dopamine, particularly its quinoid oxidation. Cys, GSH and GSSG in the model system inhibit quinoid oxidation of adrenaline as well as inhibition of superoxide (\({\text{O}}_{2}^{{\centerdot - }}\)) formation. Experiments with the superoxide-generating enzymatic reaction of xanthine and xanthine oxidase, which chemistry is different and not related to the formation of quinoid metabolites, showed that the studied substances did not inhibit \({\text{O}}_{2}^{{\centerdot - }}\) formation in this model. Thus, in this study we have shown that the biologically active sulfur-containing compounds Cys, GSH, and GSSG are specific inhibitors of quinoid oxidation of CA; it is likely that they may act as neuroprotectors. It is suggested that these compounds may be useful in the treatment and prevention of PD by activating their biosynthesis in the body.
Similar content being viewed by others
REFERENCES
Bindoli, A., Rigobello, M.P., and Galzigna, L., Toxicol. Lett., 1989, vol. 48, pp. 3−20.
Marques, F., Duarte, R.O., Moura, J.J., and Bicho, M.P., Biopl. Signals, 1996, vol. 5, pp. 275−282.
Bindoli, A., Rigobello, M.P., and Deeble, D.J., Free Radic. Biol. Med., 1992, vol. 13, pp. 391−405.
Sirota, T.V., Biomed. Khim., 2012, vol. 58, no. 1, pp. 77−87.
Sirota, T.V., Biomed. Khim., 2013, vol. 59, no. 4, pp. 399−410.
Sirota, T.V., Biomed. Khim., 2015, vol. 61, no. 1, pp. 115−124.
Smythies, J. and Galzigna, L., Biochim. Biophys. Acta, 1998, vol. 1380, pp. 159−162.
Muñoz, P., Huenchuguala, S., Paris, I., and Segura-Aguilar, J., Parkinson’s Dis., 2012, vol. 2012, 920953. https://doi.org/10.1155/2012/920953
Men’shikov, V.V. and Bol’shakova, T.D., in Adrenalin i noradrenalin (Adrenaline and Noradrenaline), Moscow: Nauka, 1964, pp. 284−293.
Rump, A.F., Schierholz, J., Rösen, R., Güttler, K., and Klaus, W., Arzneimittelforschung, 2001, vol. 51, pp. 964−970.
Costa, V.M., Silva, R., Ferreira, L.M., Branco, P.S., Carvalho, F., Bastos, M.L., Carvalho, R.A., Carvalho, M., and Remião, F., Chem. Res. Toxicol., 2007, vol. 20, pp. 1183−1191.
Kolpakov, V.G., Korsakov Zh. Nevropatol. Psykhiatr., 1974, vol. 74, pp. 1254−1263.
Smythies, J., Neurotox. Res., 2002, vol. 4, no. 2, pp. 147−150.
Smythies, J., Antioxid. Redox. Signal., 2000, vol. 2, no. 3, pp. 575−583.
Segura-Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., and Zucca, F.A., J. Neurochem., 2014, vol. 129, no. 6, pp. 898−915. https://doi.org/10.1111/jnc.12686
Smythies, J., De Iuliis, A., Zanatta, L., and Galzigna, L., Neurotox. Res., 2002, vol. 4, no. 1, pp. 77−81.
Santos, C.C., Araújo, F.M., Ferreira, R.S., Silva, V.B., Silva, J.H.C., Grangeiro, M.S., Soares, É.N., Pereira, L., Souza, C.S., Costa, S.L., Segura-Aguilar, J., and Silva, V.D.A., Toxicology In Vitro, 2017, vol. 42, pp. 54−60. https://doi.org/10.1016/j.tiv.2017.04.004
Segura-Aguilar, J. and Huenchuguala, S,. Front Neurosci., 2018, vol. 12, 106. eCollection 2018https://doi.org/10.3389/fnins.2018.00106
Jenner, P., Dexter, D.T., Sian, J., Schapira, A.H.V., and Marsden, F.R.S., Ann. Neurol., 1992, vol. 32, pp. 82−87.
Dubinina, E.E., Produkti metabolisma kisloroda v funkzional’noi aktivnosti kletok (Products of Oxygen Metabolism in Functional Activity of Cells), St. Petersburg, 2006, pp. 111−135.
Misra, H.P. and Fridovich, I., J. Biol. Chem., 1972, vol. 247, pp. 3170−3175.
Sirota, T.V., Rus. patent no. 214674, Byull. Isobret., 2000, no. 2.
Sirota, T.V., Vopr. Med. Khim., 1999, vol. 45, no. 3, pp. 263−272.
Sirota, T.V., Biomed. Khim., 2016, vol. 62, no. 6, pp. 650−655.
Kulinsky, V.I. and Kolesnichenko, L.S., Uspechi Biol. Khimii, 1990, vol. 31, pp. 157−179.
Zenkov, N.K., Lankin, V.Z., and Men’shchiko-va, E.B., Okislitelniy stress (Oxidative Stress), Moscow: Maik Nauka/Interperiodica, 2001, pp. 154−158.
Men’shchikova, E.B, Lankin, V.Z., Zenkov, N.K., Bondar,’ I.A., Krugovich, N.F., and Trufakin, V.A. (2006) Okislitelniy stress. Prooxidanty i antioxidanty (Oxidative Stress. Prooxidants and Antioxidants) Moscow: Firma Slovo, 2006, pp. 393−414.
Bannon, N.J., Goedert, M., and Williams, B., Biochem. Pharmacol., 1984, vol. 33, no. 17, pp. 2697−2698.
Perry, T.L., Godin, D.V., and Hansen, S., Neurosci. Lett., 1982, vol. 33, no. 3, pp. 305−310.
Beauchamp, C. and Fridovich, I., Anal. Biochem., 1971, vol. 44, pp. 276−287.
Sirota, T.V., Lyamina, N.E., and Weisfeld, L.I., Biofizika, 2017, vol. 62, no. 5, pp. 846−851.
Sirota, T.V., Biofizika, 2016, vol. 61, no. 1, pp. 22−27.
Lebedev, A.V., Ivanova, M.V., Timoshin, A.A., and Ruuge, E.K., Biomed. Khim., 2008, vol. 54, no. 6, pp. 687−695.
Jomova, K. and Valko, M., Toxicology, 2011, vol. 283, nos. 2−3, pp. 65−87.
Herrera-Soto, A., Díaz-Veliz, G., Mora, S., Muñoz, P., Henny, P., Steinbusc, H.W.M., and Segura-Aguilar, J., Neurotox. Res., 2017, vol. 32, no. 1, pp. 134−140. https://doi.org/10.1007/s12640-017-9719-8
Huenchuguala, S., Muñoz, P., Graumann, R., Paris, I., and Segura-Aguilar, J., Neurotoxicology, 2016, vol. 55, pp. 10−12. https://doi.org/10.1016/j.neuro.2016.04.014
Rushworth, G.F. and Megson, I.L., Pharmacol. Ther., 2014, vol. 141, no. 2, pp. 150−159. https://doi.org/10.1016/j.pharmthera.2013.09.006
Martínez-Banaclocha, M.A., Med. Hypotheses, 2012, vol. 79, no. 1, pp. 8−12.
Goldstein, D.S., **smaa, Y., Sullivan, P., Sharabi, Y., Neurochem. Res., 2017, vol. 42, no. 11, pp. 3289−3295. https://doi.org/10.1007/s11064-017-2371-0
Coles, L.D., Tuite, P.J., Öz, G., Mishra, U.R., Kartha, R.V., Sullivan, K.M., Cloyd, J.C., and Terpstra, M., J. Clin. Pharmacol., 2018, vol. 58, no. 2, pp. 158−167. https://doi.org/10.1002/jcph.1008
https://natureweight.ru/glutation/
Izumi, Y., Yakugaku Zasshi, 2013, vol. 133, no. 9, pp. 983−988.
Zenkov, N.K., Men’shchikova, E.B., and Tkachev, V.O., Biochemistry (Moscow), 2013, vol. 78, no. 1, pp. 27−47.
Lee, J.A., Son, H.J., Choi, J.W., Kim, J., Han, S.H., Shin, N., Kim, J.H., Kim, S.J., Heo, J.Y., Kim, D.J., Park, K.D., and Hwang, O., Neurochem. Int., 2018, vol. 112, pp. 96−107. https://doi.org/10.1016/j.neuint.2017.11.006
Tarazi, F.I., Sahli, Z.T., Wolny, M., and Mousa, S.A., Pharmacol. Ther., 2014, vol. 144, no. 2, pp. 123−133. https://doi.org/10.1016/j.pharmthera.2014.05.010
ACKNOWLEDGMENTS
The author is grateful to N.E. Lyamina for technical assistance in this study.
Funding
This work was partially supported by the Agreement 03/2018-ACS of February 2, 2018.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any research involving humans or using animals as research objects.
The author declares no conflict of interest.
Additional information
Translated by A. Medvedev
Rights and permissions
About this article
Cite this article
Sirota, T.V. The Effect of Sulfur-Containing Compounds on the Quinoid Process of Adrenaline Autoxidation; Potential Neuroprotectors. Biochem. Moscow Suppl. Ser. B 14, 62–69 (2020). https://doi.org/10.1134/S199075082001014X
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S199075082001014X